<?xml version="1.0" encoding="utf-8" ?>
<INTERACTIONS>
<INTERACTION>
<SOURCE>
<CLINICAL_SOURCE>ANSM</CLINICAL_SOURCE>
<SOURCE_FILE>19-DOPAMINERGIC-ALKALOIDS-OF-ERGOT-OF-RYE.html
</SOURCE_FILE>
</SOURCE>
<DRUG1>
<CLASS name="DOPAMINERGIC ALKALOIDS OF ERGOT OF RYE " code="G02CB-001" /></DRUG1>
<DRUG2>
<CLASS name="VASOCONSTRICTOR ALKALOIDS OF ERGOT OF RYE" code="N02CA0-001" /></DRUG2>
<DESCRIPTION>Risk of constriction of blood vessels and/or rapid elevation of blood pressure</DESCRIPTION>
<SEVERITY>Not Recommended</SEVERITY>
</INTERACTION>
<INTERACTION>
<SOURCE>
<CLINICAL_SOURCE>ANSM</CLINICAL_SOURCE>
<SOURCE_FILE>19-DOPAMINERGIC-ALKALOIDS-OF-ERGOT-OF-RYE.html
</SOURCE_FILE>
</SOURCE>
<DRUG1>
<CLASS name="DOPAMINERGIC ALKALOIDS OF ERGOT OF RYE " code="G02CB-001" /></DRUG1>
<DRUG2>
<CLASS name="ANTIPARKINSONIAN ANTICHOLINERGICS" code="N04AA-001" /></DRUG2>
<DESCRIPTION>Risk of increase of neuropsychological disorders

</DESCRIPTION>
<SEVERITY>Precaution for use:</SEVERITY>
<COMMENT>Regular clinical and biological monitoring, especially at the beginning of the administration of these substances together. </COMMENT>
</INTERACTION>
<INTERACTION>
<SOURCE>
<CLINICAL_SOURCE>ANSM</CLINICAL_SOURCE>
<SOURCE_FILE>19-DOPAMINERGIC-ALKALOIDS-OF-ERGOT-OF-RYE.html
</SOURCE_FILE>
</SOURCE>
<DRUG1>
<CLASS name="DOPAMINERGIC ALKALOIDS OF ERGOT OF RYE " code="G02CB-001" /></DRUG1>
<DRUG2>
<CLASS name="MACROLIDES (EXCEPT SPIRAMYCIN)" code="J01FA" /></DRUG2>
<DESCRIPTION>Increase of the plasma concentrations of the dopaminergic with possible increase of its activity or appearance of signs of overdose. </DESCRIPTION>
<SEVERITY>Not recommended</SEVERITY>
</INTERACTION>
<INTERACTION>
<SOURCE>
<CLINICAL_SOURCE>ANSM</CLINICAL_SOURCE>
<SOURCE_FILE>19-DOPAMINERGIC-ALKALOIDS-OF-ERGOT-OF-RYE.html
</SOURCE_FILE>
</SOURCE>
<DRUG1>
<CLASS name="DOPAMINERGIC ALKALOIDS OF ERGOT OF RYE " code="G02CB-001" /></DRUG1>
<DRUG2>
<CLASS name="ALPHA SYMPATHOMIMETICS (ORAL AND/OR NASAL)" code="R01AA" /></DRUG2>
<DESCRIPTION>Risk of constriction of blood vessels and/or rapid elevation of blood pressure

</DESCRIPTION>
<SEVERITY>Not recommended</SEVERITY>
</INTERACTION>
<INTERACTION>
<SOURCE>
<CLINICAL_SOURCE>ANSM</CLINICAL_SOURCE>
<SOURCE_FILE>19-DOPAMINERGIC-ALKALOIDS-OF-ERGOT-OF-RYE.html
</SOURCE_FILE>
</SOURCE>
<DRUG1>
<CLASS name="DOPAMINERGIC ALKALOIDS OF ERGOT OF RYE " code="G02CB-001" /></DRUG1>
<DRUG2>
<CLASS name="INDIRECT SYMPATHOMIMETICS" code="C01CA-R01BA" /></DRUG2>
<DESCRIPTION>Risk of constriction of blood vessels and/or rapid elevation of blood pressure

</DESCRIPTION>
<SEVERITY>Not recommended</SEVERITY>
</INTERACTION>
</INTERACTIONS>
